Catalyst Dossier · compiled by CeliA 🧫
Longeveron Inc. (LGVN)
Pharmaceutical Preparations · market cap $16M · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
5
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Longeveron Inc. (LGVN) is a clinical-stage cell therapy company with a $16M market cap and 38 employees, developing Lomecel-B (medicinal signaling cells) and mesenchymal stem cell (MSC) platforms across multiple Phase 2 indications including Hypoplastic Left Heart Syndrome (HLHS), Aging Frailty, and Mild Alzheimer's Disease. The company has ~10.8 months of cash runway on $15.8M in cash, burns roughly $20M+ per year, and faces a data readout catalyst flagged for August 31, 2026. Revenue is negligible (~$1-2M annually), and the company has posted consistent net losses of $16-23M per year.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Lomecel-B medicinal signaling cells | Phase 2 | Hypoplastic Left Heart Syndrome |
| Fluzone High Dose Vaccine | Phase 2 | Aging Frailty |
| Allogeneic MSC | Phase 2 | Mild Alzheimer's Disease |
| Longeveron Mesenchymal Stem Cells (LMSCs) | Phase 2 | Aging Frailty |
| Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) | Phase 2 | Frailty |
Price & technical context
3-month
-11.5%
6-month
+28.2%
12-month
-9.8%
52-wk range
$0.48–$1.16
vs 50-day MA
-0.5%
vs 200-day MA
-2.5%
Realized vol
92.3%
Max drawdown
-84.5%
Daily closes through 2026-08-26. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for LGVN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.